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Introduction: A still not well defined proportion of patients with multiple myeloma (MM) and eligible for
autologous stem cell transplantation (AuSCT) fails to mobilize CD34+ peripheral blood stem cells (PBSC) at all or to
collect an adequate number for a safe procedure or sufficient for multiple transplants. These so-called “poor-mobilizers”
are difficult to be predicted, due to marked difference across previous heterogeneous studies.
Methods: We aimed to develop a method based on simple clinical parameters for predicting unsuccessful (<2 × 106/kg)
or sub-optimal (<5 × 106/kg) collections of CD34+ PBSC in newly diagnosed MM patients eligible for AuSCT,
treated with novel agents and receiving an homogeneous mobilizing therapy with cyclophosphamide and
granulocyte-colony stimulating factor (G-CSF). To this purpose, 1,348 patients enrolled in five consecutive Italian
clinical trials were retrospectively analysed. Age, baseline low peripheral blood cell counts, use of lenalidomide,
and haematological toxicity developed during induction were taken into account as possible factors associated
with poor mobilization.
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Results: Overall, 280 patients (20.8%) showed either sub-optimal (167 patients, 12.4%) or unsuccessful (113
patients, 8.4%) collections. All analysed parameters negatively influenced the procedure, but only age and
haematological toxicity during induction maintained their significance at multivariate analysis. Based on ordinal
logistic regression model, we constructed a risk heat-map where the four parameters were pooled and weighted
according to their relevance as single or combined variables. This model was predictive for different probabilities
of failure, suboptimal or optimal outcomes.
Conclusions: We found that about one fifth of newly diagnosed MM fails to collect an adequate number of
PBSC. Our model, based on a large group of patients treated frontline with novel agents and receiving the most
popular mobilizing approach currently employed in Europe, is applicable in individual subjects and may
contribute to the early identification of “poor mobilizer” phenotypes.Introduction
Multiple myeloma (MM) is a neoplastic plasma cells dis-
order accounting for approximately 13% of all hematologic
malignancies [1]. In Europe, melphalan-prednisone
(MP) plus thalidomide (MPT) or bortezomib (MPV)
represent the initial standards of care for elderly MM
patients [2,3], while induction therapy including novel
agents followed by autologous stem cell transplant-
ation (AuSCT) is the gold standard for frontline treat-
ment of younger, transplant-eligible subjects [3,4].
Notwithstanding, a variable proportion of these last
patients fails to mobilize CD34+ peripheral blood stem
cells (PBSC) at all, or to collect an adequate number of
these cells for a safe AuSCT or sufficient for additional
transplants [5-7]. The percentage of these ‘poor mobi-
lizers’, however, differs across studies, depending on
definitions, parameters utilized to evaluate collections,
age, disease type, phase and characteristics, treatments
applied, objectives to reach, and practices for mobilization
and apheresis [8,9]. Due to such heterogeneity, data are
difficult to analyze and to compare.
This study aimed to evaluate the rate of unsatisfactory
CD34+ PBSC collections and to investigate the possible
role of some easily available clinical parameters in pre-
dicting this phenomenon in MM patients eligible for
AuSCT, treated at diagnosis with novel agents and
homogeneously mobilized with cyclophosphamide and
granulocyte-colony stimulating factor (G-CSF), which is
the principal approach currently employed in Europe.
Methods
Overall, 1,348 newly diagnosed patients with MM en-
rolled in five consecutive clinical trials conducted by
GIMEMA/Multiple Myeloma Italian Network were
retrospectively evaluated [10-14]. According to the dif-
ferent study protocols, induction regimens consisted of:
1) thalidomide + dexamethasone (TD: 316 patients; clin-
ical trial number NTC01341262 – clinicaltrials.gov, reg-
istered 11 January 2004); 2) bortezomib, thalidomide and
dexamethasone (VTD: 258 patients; clinical trial numberNCT01134484 – clinicaltrials.gov, registered 28 May
2010); 3) lenalidomide and dexamethasone (RD, 396 pa-
tients; clinical trial numbr NCT00551928 – clinicaltrials.
gov, registered 30 October 2007); 4) pegylated liposomal
doxorubicin, bortezomib, and dexamethasone (PAD, 86
patients; clinical trial Eudract number 2005-004714-32 –
AIFA, registered 30 September 2005); 5) a further group
of 292 patients receiving a modified VAD induction regi-
men (doxorubicin, vincristine and dexamethasone), not
including novel agents (clinical trial number AOGIBAT-
III-2004-002, registered 07 May 2004) was also evalu-
ated. In all these patients the impact on CD34+ PBSC
collection of: 1) age (>60 years), 2) initial use of lenali-
domide (up to four cycles), 3) cytopenia at diagnosis
(Hb <10 g/dl, neutrophil count <1 × 109/L, platelet
count <100 × 109/L: at least one), and 4) grade 3 to 4
hematological toxicity during induction therapy (CTCAE
v4) was analyzed. All these parameters are generally be-
lieved potentially able to negatively affect releasing of
PBSC and to impair their collection in MM [15-18]. Ini-
tially, we also considered extensive radiotherapy to mar-
row bearing tissue, which was, however, excluded in the
final analysis, as the number of patients who underwent
such a treatment was very small and almost entirely com-
prised within the group developing cytopenia during
induction.
In all cases, the mobilizing regimen was cyclophospha-
mide (3 to 4 g/sqm) + G-CSF (10 mcg/kg), given in two
daily divided doses, without the addition of the mobiliz-
ing agent plerixafor, a drug still not available at the time
of the evaluated trials. The morning dose of G-CSF was
omitted on the harvest day. An absolute CD34+ PBSC
number >20/μl was the threshold to start apheresis. Due
to the retrospective nature of the study, which included
patients enrolled over a prolonged period of time, apher-
esis machines, characteristics and methods of collection
were progressively adjusted, according to available stan-
dards. In most patients, however, the amount of blood
processed was twice the calculated total blood volume,
by using Cobe Spectra or Fresenius AS series machines,
Table 1 Distribution of the analyzed parameters in the
whole population
Parameters Total number (%)
Age
<60 years 788 (58.46%)
≥60 years 560 (41.54%)
Lenalidomide use
No 992 (73.59%)
Yes 356 (26.41%)
Hematological toxicity
No 1260 (93.47%)
Yes 88 (6.53%)
Baseline cytopenia
No 1016 (75.37%)
Yes 332 (24.63%)
Number of parameters
0 402 (29.82%)
1 630 (46.74%)
2 252 (18.69%)
3 54 (4.01%)
4 10 (0.74%)
Distribution of the four analyzed parameters potentially affecting PBSC
collection in 1,348 newly diagnosed myeloma patients. Lenalidomide use: up
to four cycles; baseline cytopenia: Hb <10 g/dl, neutrophil count <1 × 109/L,
platelet count <100 × 109/L: at least one at diagnosis; hematological toxicity:
grade 3 or 4 during induction therapy (CTCAE v4). PBSC, peripheral blood
stem cells.
Table 2 Distribution of failure, suboptimal and optimal
collections in the whole population
Parameters Failure Sub-Optimal Optimal
Number (%) Number (%) Number (%)
Whole population
Outcome 167 (12.39) 113 (8.38) 1068 (79.23)
Age
<60 years 80 (10.15) 57 (7.23) 651 (82.61)
≥60 years 87 (15.54) 56 (10.00) 417 (74.46)
Lenalidomide use
No 113 (11.39) 78 (7.86) 801 (80.75)
Yes 54 (15.17) 35 (9.83) 267 (75.00)
Hematological toxicity
No 132 (10.48) 106 (8.41) 1022 (81.11)
Yes 35 (39.77) 7 (7.95) 46 (52.27)
Baseline cytopenia
No 117 (11.52) 80 (7.87) 819 (80.61)
Yes 50 (15.06) 33 (9.94) 249 (75.00)
Absolute numbers and percentages of failures, suboptimal and optimal
collections, according to the presence of different risk factors in 1,348 newly
diagnosed myeloma patients. Failure: CD34+ PBSC <2 × 106/kg; Suboptimal:
CD34+ PBSC >2 and <5 × 106/kg; Optimal: CD34+ PBSC >5 × 106/kg. PBSC,
peripheral blood stem cells.
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5 × 106/kg. CD34+ PBSC total amounts after a single
mobilization procedure <2 × 106/kg (the minimum tar-
get cell dose usually required to proceed to AuSCT)
and >2/<5 × 106/kg (a cell dose ensuring a safe and
rapid marrow recovery, as well as the possibility to per-
form at least two AuSCT) were considered ‘failures’ or
‘sub-optimal’ results, respectively. Data were collected
from two databases (Turin and Bologna). No formal
ethical approval and/or consent form were needed for
this study, according to current Italian law, as it was a
retrospective, observational study, which was, however,
performed according to Helsinki Declaration principles
for experimental research on humans.
All risk factors were analyzed by univariate and multi-
variate logistic regression, taking into consideration two
models having as outcome the risk to have a ‘failure’ or
that of a ‘sub-optimal’ collection. The results were internally
validated using the bootstrap method. In addition, receiver
operating characteristic (ROC) curves were constructed
to assess model discriminatory power for the predictive
probability. The proportional odds assumption was
evaluated by the Brant test. Finally, predicted probabil-
ities of outcomes, based on the ordinal logistic regres-
sion model (optimal versus suboptimal versus failure),
were used to generate a patient-based risk heat-map
where the four parameters were pooled and weighted
according to their relevance as single or combined vari-
ables. Statistical analysis was performed using the STATA
analysis program, version 11.0 (Stata Corp., College Sta-
tion, TX, USA).
Results
The distribution of analyzed parameters in the whole
population is reported in Table 1. Among the 1,348 pa-
tients evaluated, 402 (29.8%) had no ‘negative’ parame-
ters, while 946 (70.2%) showed at least one of them; in
particular, 630 patients (46.7%) had only one parameter,
while 319 patients showed a combination of two (252,
18.7%), three (54, 4.0%) or four (10, 0.7%) parameters,
respectively. Overall, 560 patients (41.5%) were more
than 60 years old, 332 patients (24.6%) had baseline cy-
topenia, 356 patients (26.4%) were treated with lenalido-
mide and 88 patients (6.5%) developed grade 3 or 4
hematological toxicity under induction therapy.
After a single mobilizing procedure (median of leuka-
pheresis: 2; range: 0 to 4), 280 patients (20.8%) collected
an insufficient number of CD34+ PBSC, including 167 pa-
tients (12.4%) with unsuccessful and 113 patients (8.4%)
with sub-optimal collections, respectively (Table 2). An or-
dinal logistic regression model showed that each single
parameter negatively influenced collections at univariate
analysis (Table 3); at multivariate analysis, however, only
hematological toxicity developed during induction and
Table 3 Ordinal logistic regression model
Parameters Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
Age 1.63 1.25 to 2.12 0.0001 1.62 1.24 to 2.13 0.0001
Lenalidomide use 1.4 1.05 to 1.85 0.021 1.2 .89 to 1.63 0.217
Hematological toxicity 4.51 2.92 to 6.97 0.0001 3.9 2.48 to 6.14 0.0001
Baseline cytopenia 1.38 1.03 to 1.85 0.029 1.33 .98 to 1.8 0.062
Univariate and multivariate analysis of risk factors analyzed. Statistical significance was defined as P <0.05. CI, confidence interval; OR odds ratio.
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effect on mobilization (Table 3). Data regarding the effect
of other induction regimens on PBSC collection indicated
that the use of agents such as bortezomib, thalidomide
and doxorubicin did not negatively influence PBSC collec-
tions (data not shown). Figure 1a illustrates the risk heat-
map obtained based on an ordinal logistic regression
model. According to the cumulative probability of unsuc-
cessful collections (failures + suboptimal), four different
areas were identified, respectively, at low (range 14% to
18%), intermediate-1 (21% to 30%), intermediate-2 (39%
to 46%), and high (50% to 63%) risk. In particular, the pos-
sibility of a complete failure ranged from 9% for lowest-
risk, to 40% for highest-risk patients. Interestingly, the
number of parameters also paralleled the risk of unsatis-
factory collections in 1,203 patients (89.24% of the entire
population) reaching 20/μl (or more) circulating CD34+
PBSC at the time of apheresis (Figure 1b). All these find-
ings did not differ significantly when the 294 patients who
had not received novel agents were excluded from the
analysis (data not shown). Finally, ROC curves, based on
the logistic regression model (Additional file 1), depicted
an area under the curve (AUC) of 0.63 and 0.62, respect-
ively, in discriminating patients with failure or sub-optimal
outcome (Additional file 2).
Discussion
An insufficient availability of PBSC may be a relevant
clinical problem in patients otherwise eligible for
AuSCT, a procedure that represents the best therapeutic
approach in MM. We quantified this phenomenon,
showing that a significant proportion of previously un-
treated MM patients (at least one out of five) completely
fails CD34+ PBSC collection or does not reach an ad-
equate number after a standard mobilizing procedure.
Our results also show that older age, baseline cytopenia
and severe hematological toxicity during the induction
treatment (which likely suggest a more compromised
marrow function) may be useful to highlight patients at
risk of an impaired release of PBSC in newly diagnosed
MM. Of interest, in our series, some patients with
hematological toxicities due to induction treatment also
showed one or more cytopenias at the time of diagnosis,
before any treatment; both of these parameters hadsingly a negative impact on harvest at univariate analysis.
However, when the results were investigated in multi-
variable analysis using two different assays (ordinal
outcome and logistic regression), only hematopoietic
toxicity remained statistically significant, while low base-
line peripheral blood cell counts did not. The use of lenali-
domide has also been considered a possible risk factor,
although patients receiving lenalidomide-based regimens
can be mobilized with appropriate strategies [19]. In par-
ticular, a short course of lenalidomide did not affect PBSC
harvest in patients treated with cyclophosphamide plus G-
CSF as mobilizing therapy [20]. In that study, however, the
percentage of inadequate yield (<4 × 106 CD34+ PBSC)
after a single mobilization was similar to that (21%) ob-
served in our study. Overall, we confirm a possible nega-
tive effect of lenalidomide on CD34+ PBSC collection and
this should be taken into consideration when planning
mobilization in patients with other potential risk factors,
such as cytopenia.
Predicting mobilization failure using clinical variables
has been demonstrated to be often inaccurate [8]. In this
setting, algorithms based on the so-called ‘pre-emptive’
or ‘just in time’ evaluation of circulating CD34+ PBSC
have been shown to be useful in predicting failure, allow-
ing an immediate and appropriate addition of plerixafor to
the original mobilization regimen and resulting in im-
provement of PBSC collection rates [21-25]. However,
even among subjects with an apparently adequate number
of circulating CD34+ PBSC at the time of apheresis
(>20/μl), there may be a not negligible percentage of pa-
tients (5% to 10% in the literature, about 12% in our
series) still achieving poor or sub-optimal results [26,27].
As a consequence, the rate of harvest failure in MM is
usually higher than the rate of mobilization failure. The
majority of these discrepancies can probably be ascribed
to variability in mobilization, collection efficiency, prema-
ture termination of apheresis dictated by clinical problems
arising during the procedure, reduced flow from central
venous catheter, or poor intra-apheresis mobilization [28].
In any case, our ‘composed’ risk model was able to identify
these patients at risk of a poor harvest, although poten-
tially considered good-mobilizers, thus selecting a further
population in which the use of plerixafor could be
considered.
Figure 1 Predictive risk heat-map. a) Predictive risk heat-map, applicable in individual patients, in which probabilities of failures, suboptimal
and optimal collections, according to relevance of risk factors as single or combined variables, were distributed in four different and growing
(from green to red) risk areas. Data were generated in the whole population of 1,348 newly diagnosed multiple myeloma patients; b) Predictive
risk heat-map in patient population (number, 1,203, 89.24%) with an absolute number of circulating CD34+ PBSC >20/μl at the time of apheresis.
PBSC, peripheral blood stem cells.
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zers’ has been recently proposed by GITMO, which
employed an analytic hierarchy process able to analyze
quantitative and qualitative aspects of a decision need
when a poor information base is available [7,29]. This pro-
posal, however, based on clinical and laboratory criteria,
included lymphomas, as well as patients with advanced/
refractory disease, multiple lines of prior treatments, failure
of previous mobilization attempts, extensive radiotherapyand reduced marrow cellularity or large neoplastic in-
volvement at the time of mobilization. Indeed, our study,
in which all patients had newly diagnosed MM achieving
at least a partial response after induction treatment, repre-
sents a completely different scenario.
Based on four simple clinical parameters, our model
was, not unexpectedly, not completely predictive (see
AUC reported in Additional file 2). Taking into consid-
eration other variables (that is, the pharmacogenetic
Musto et al. Stem Cell Research & Therapy  (2015) 6:64 Page 6 of 7background of mobilizing and induction regimens)
could certainly improve its performance, probably at
the expense, however, of a wide application in daily
practice.
Conclusions
To conclude, about 20% of newly diagnosed MM fail to
collect an adequate number of PBSC. Our simple ‘risk
card’, based on the largest group of patients treated
frontline with novel agents and receiving the most popu-
lar mobilizing approach currently employed in Europe
so far reported in this setting, is applicable in individual
patients with MM and may contribute to the early iden-
tification of ‘poor mobilizer’ phenotypes. Although cer-
tainly ameliorable, this model increases our awareness in
this field, representing a novel possible framework to
select patients in whom to plan alternative mobilizing
strategies [30,31]. Therefore, its validation in prospective
series is required, possibly even in the setting of poten-
tially more effective chemotherapy-free-mobilizing regi-
mens, which have been recently reported as superior to
the cyclophosphamide and G-CSF combination [27,32].
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Additional file 1: Logistic regression model. Univariate and
multivariate analysis of risk factors, taking into consideration two
models having as outcome the risk to have a ‘failure’ or that of a
‘sub-optimal’ collection. Statistical significance was defined as P <0.05.
Additional file 2: Receiver operating characteristic curves (ROC) of
logistic regression model. ROC curves assessing the model
discriminatory power for the predictive probability of failure and
suboptimal harvests, respectively. (PDF 160 kb)
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